Johns Hopkins Drug Discovery - Course - Drug Discovery Case Studies
90
page-template,page-template-full_width,page-template-full_width-php,page,page-id-90,page-child,parent-pageid-25,bridge-core-3.0.5,qi-blocks-1.0.6,qodef-gutenberg--no-touch,qodef-qi--no-touch,qi-addons-for-elementor-1.5.5,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-29.1,qode-theme-bridge,disabled_footer_bottom,wpb-js-composer js-comp-ver-6.9.0,vc_responsive,elementor-default,elementor-kit-3247,x-shortcodes-v3_0_5

Drug Discovery Case Studies (ME:200.707)

Home > Our Courses > Drug Discovery Case Studies (ME:200.707)

“Drug Discovery Case Studies” is designed to provide students with insights into the ever-changing landscape of drug discovery research by presenting case studies for various breakthrough drugs discovered since the 1940s. Each lecture selects a particular drug that has made a significant impact on patients’ lives and examines some key elements that have contributed to its successful discovery and development. The course is given by the lecturers that participated in “Introduction to Drug Discovery Research”. The final three lectures will be given by guest speakers who will present case studies on new drugs in which they were directly involved at the time of discovery and development.

Fall 2022
Course Director: Takashi Tsukamoto ([email protected])
Location: Rangos 590 
Time: 10:00 AM – 11:30 AM
Dates: Every Friday 9/9/2022-12/16/2022

Prerequisite:

No prior knowledge in drug discovery is required. This course is recommended for students in the 2nd or later year of their graduate program.

Grades will be determined by:

(i) class participation (25%); (ii) group project (50%) where 5-6 students will form a team to prepare a case study presentation; (iii) critique paper (25%) on one of the two other students’ presentations. 

All students with disabilities who require accommodations for this course should contact Catherine L. Will, Disability Services Coordinator for Graduate Biomedical Education ([email protected] or 410-614-3781) at their earliest convenience to discuss their specific needs. Please note that accommodations are not retroactive.

 

Course Schedule

  Topic Lecturer
9/9 Introduction Takashi Tsukamoto
9/16 Penicillin Takashi Tsukamoto
9/23 Methotrexate Kathryn Lemberg
9/30 Propranolol Jim Barrow
10/7 Captopril David Meyers
10/14 Omeprazole Diane Peters
10/21 Aripiprazole Takashi Tsukamoto
10/28 Tixagevimab/Cilgavimab (Evusheld®) Mark Esser (AstraZeneca)
11/4 Nirmatrelvir/Ritonavir (Paxlovid®) Claire Steppan (Pfizer)
11/11 Risdiplam (Evrysdi®) Alexander Stephan (Roche)
11/18 Group Discussion  
12/2 Case Study Presentation 1 Students
12/9 Case Study Presentation 2 Students
12/16 Case Study Presentation 3 Students
     
     
     

 Past Guest Lectures

  Topic Lecturer
10/31/12 Eribulin Bruce Littlefield (Eisai)*
 11/7/12  Denosumab  Scott Simonet (Amgen)*
 11/14/12  Raltegravir  Steve Young (formerly at Merck)*
 10/29/14  Tafacitinib Chakrapani Subramanyam (Pfizer)
 11/5/14 Trastuzumab emtansine  Gail Phillips (Genentech)
 11/12/14 Linaclotide Caroline Kurtz (Ironwood Pharma)
 10/28/16  Ledipasvir/Sofosbuvir (Harvoni®)  Michael Sofia (Arbutus Biopharma, Inc.)
 11/4/16  Mepolizumab (Nucala®)  Steven Yancey (GlaxoSmithKline)
 11/11/16  Lumacaftor/Ivacaftor (Orkambi®)  Mark Miller (Vertex Pharmaceuticals Inc.)
10/19/18 Etelcalcetide (Parsabiv®) Les Miranda (Amgen)
11/2/18 Durvalumab (Imfinzi®) Scott Hammond (MedImmune)
11/9/18 Suvorexant (Belsomra®) Anthony Roecker (Merck)
10/30/20 Erenumab (Aimovig®) Cen Xu (Amgen)
11/6/20 Elexacaftor/ivacaftor/tezacaftor (Trikafta®) Mark Miller (Vertex Pharmaceuticals)
11/13/20 Ivosidenib (Tibsovo®) Zenon Konteatis (Agios Pharmaceuticals)